![]() |
Volumn 19, Issue 6, 2008, Pages 1209-1210
|
COX-2 targeting in cancer: A new beginning?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CAPECITABINE;
CELECOXIB;
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITOR;
FLUOROPYRIMIDINE DERIVATIVE;
ROFECOXIB;
ZILEUTON;
ADVANCED CANCER;
ANTINEOPLASTIC ACTIVITY;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER PREVENTION;
CARDIOTOXICITY;
CHEMOPROPHYLAXIS;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
DRUG COST;
DRUG EFFICACY;
DRUG TARGETING;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
GASTROINTESTINAL TOXICITY;
HUMAN;
LETTER;
LUNG NON SMALL CELL CANCER;
MONOTHERAPY;
NEOPLASM;
PANCREAS CANCER;
POSTMARKETING SURVEILLANCE;
PREDICTION;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEIN EXPRESSION;
TREATMENT OUTCOME;
UNSPECIFIED SIDE EFFECT;
ANTINEOPLASTIC AGENTS;
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITORS;
DRUG THERAPY, COMBINATION;
HUMANS;
NEOPLASMS;
|
EID: 44849137509
PISSN: 09237534
EISSN: 15698041
Source Type: Journal
DOI: 10.1093/annonc/mdn286 Document Type: Letter |
Times cited : (3)
|
References (5)
|